POPULARITY
2 episodes with Immunosuppression
2 episodes with Immunosuppression
4 episodes with Immunosuppression
2 episodes with Immunosuppression
3 episodes with Immunosuppression
3 episodes with Immunosuppression
3 episodes with Immunosuppression
3 episodes with Immunosuppression
2 episodes with Immunosuppression
Broadcast from KSQD, Santa Cruz on 5-21-2026: This is the second show featuring Mira Achilles, a UCSC graduate working on her masters in epidemiology. Dr. Dawn and Mira open with a Harvard study showing OpenAI's o1 reasoning model reached correct diagnoses 67% of the time versus 50-55% for physicians, and scored 89% versus 34% on treatment plans. The AI advantage shrinks when doctors get more data and time, suggesting its greatest value is in fast-moving triage. Dr. Dawn cautions that over-reliance on AI during residency could undermine the clinical reasoning neurologic pathways doctors must develop, and emphasizes the "zebra paradox"— rare diseases remain rare even when symptoms match the textbook. Dr. Dawn shares a personal case of a patient with throat shingles, leading her to use a medical AI (OpenEvidence) to investigate Shingrix risks. An Australian study found an elevenfold increase in shingles within 21 days of the first Shingrix dose in adults over 65, though dose two reduced overall risk by 73%. She explains this could be one of several things such as immune reconstitution inflammatory syndrome (IRIS), or that the AS01B vaccine adjuvant's strong activation may transiently reactivate latent virus, and recommends valacyclovir prophylaxis for high-risk patients for their first Shringrex shot.. Mira discusses AI in education, noting the shift from professors threatening plagiarism charges to teaching students how to critique AI output, emphasizing taking summaries "with a grain of salt." Dr. Dawn describes Chinese research scanning 1,154 children that identified a third ADHD subtype—severe emotional dysregulation—showing 45 abnormal brain regions versus 26 in the inattentive and hyperactive-impulsive types, with standard stimulants working poorly for this group. She connects this to traditional psychiatric personality disorder classifications and A discussion of vagus nerve stimulation's emerging applications for autoimmune conditions. Dr. Dawn and Mira discuss menstruation and bodily autonomy, then describe the Somedays period pain simulator that uses electrical impulses to let men experience menstrual cramps, highlighting differing pain thresholds. An emailer references a Radiolab episode about deliberate hookworm infection to treat asthma and allergies. Dr. Dawn explains parasites release immunosuppressants to survive, including anti-inflammatory protein-2 (AIP) now in drug development, which stimulates T-regulatory cells and IL-10 while "alarmins" inhibit lung inflammation—though this increases vulnerability to new infections. A caller with H. pylori and frequent viral infections asks whether S. boulardii and reuteri probiotics are safe given her low immunity. Dr. Dawn explains immunosuppression warnings target transplant-level drug suppression, not a tendency toward viruses like hers. Dr. Dawn thinks that her near-zero natural killer cells explain frequent infections, and suggests that the H. pylori test given her absence of symptoms, may be an incidental bystander rather than the cause of her low ferritin, which suggests bleeding. In medical news of the weird, Dr. Dawn describes Baby Cassian, diagnosed in utero with congenital high airway obstruction syndrome (CHAOS), who was partially removed from the womb at 25 weeks for airway surgery, returned, and born again at 31 weeks—leading to a discussion of microsurgery and how specialties partition by the physical scale of the surgery rather the location or type of structure.
This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Dr. Zhi Lin, Chief Director of Cardiovascular Surgery Division 1 at Xiamen Cardiovascular Hospital of Xiamen University in Xiamen, China, and Dr. Oscar A. Flores Flores, a cardiothoracic surgeon at Hospital Civil de Guadalajara Fray Antonio Alcalde in Guadalajara, Mexico, about The Heart Sapling Visiting Scholar Program. Chapters 00:00 Intro 02:22 AATS, UAE Conference, King Faisal 05:28 JANS 1, LAA Closure vs Therapy AF 09:53 JANS 2, Thrombus-Free LAA Occlusion 11:49 JANS 3, Immunosuppression & Retransplantation 13:06 JANS 4, Biomarkers & Outcomes Isolated CABG 15:18 Video 1, Rheumatic MV Reconstruction 17:02 Video 2, Morgagni Hernia 18:07 Video 3, Robotic Excision Anterior Mediastinal 19:35 Lin Zhi & Oscar Flores, Chinese Fellowship & Surgery 34:25 Upcoming Events 35:13 Closing Dr. Flores discusses what the program entails, sharing his experience as a fellow and the opportunities he gained from it. Dr. Lin then outlines the program's goals and the various procedures that can be learned at Xiamen Cardiovascular Hospital of Xiamen University, which hosts the program. They also cover how to join the program and the application process. Furthermore, they discuss minimally invasive procedures in China and how this approach is growing in popularity. Joel also highlights recent JANS articles on left atrial appendage closure or medical therapy in atrial fibrillation, long-term thrombus-free left atrial appendage occlusion via magnetofluids, implications of immunosuppression and retransplantation for donor-derived cell-free DNA associated with increased risk of chronic lung allograft dysfunction and mortality, and immunosenescence biomarkers and outcomes in isolated coronary artery bypass grafting. In addition, Joel explores rheumatic mitral valve reconstruction, tips for the surgical management of a Morgagni hernia, and right robotic excision of anterior mediastinal mass. Before closing, Joel highlights upcoming events in CT surgery. JANS Items Mentioned 1. Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation 2. Long-Term Thrombus-Free Left Atrial Appendage Occlusion Via Magnetofluids 3. Donor-Derived Cell-Free DNA Associated With Increased Risk of Chronic Lung Allograft Dysfunction and Mortality: Implications of Immunosuppression and Retransplantation 4. Immunosenescence Biomarkers and Outcomes in Isolated Coronary Artery Bypass Grafting CTSNet Content Mentioned 1. Rheumatic Mitral Valve Reconstruction 2. Tips for the Surgical Management of a Morgagni Hernia 3. Right Robotic Excision of Anterior Mediastinal Mass Other Items Mentioned 1. Endoscopic Cone Repair in an Adult Patient With Ebstein Anomaly 2. CTSNet Website Redesign: Important Updates and Transition Details 3. Career Center 4. CTSNet Events Calendar Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.
This special Tick Boot Camp Podcast crossover features the full International Lyme and Associated Diseases Society (ILADS) webinar recording, “At the Frontlines of Chronic Illness: Conversations with ILADS Experts.” In this dynamic panel discussion, leading clinicians and specialists unpack why Lyme disease and other infection-associated chronic illnesses are so misunderstood, why testing fails so many patients, and what it really takes to heal—brain, immune system, mitochondria, and terrain included. Moderated by Rich Johannesen (Tick Boot Camp), the panel delivers practical insights and hopeful, patient-centered guidance for anyone navigating complex chronic illness—whether you're a patient, caregiver, clinician, or advocate. Featured Panelists Chris Winfrey, MD — Psychiatrist; Medical Director, New Image Wellness Nicole Bell — “The Lyme Disease Engineer”; CEO, Galaxy Diagnostics Tania Dempsey, MD — Medical Director, AIM Center for Personalized Medicine Melanie Stein, ND — Naturopathic Doctor; Author focused on cellular wellness and healing terrain Host/Moderator: Rich Johannesen (Tick Boot Camp) ILADS Intro: Ali Moresco (ILADS) Episode Highlights ILADS Mission and Why This Webinar Matters The webinar opens with ILADS' mission: improving diagnosis and treatment of Lyme disease and associated illnesses through research, education, and policy. ILADS emphasizes physician training and patient-centered care, while also supporting the educational mission of ILADEF. Rich frames the night as a rare opportunity to hear from experts working at the front lines of complex chronic illness—especially for patients who've been dismissed, misdiagnosed, or told their symptoms “don't make sense.” Segment 1: Brain Health, Neuroimmune Illness, and Why Lyme “Feels Like Dementia” Chris Winfrey, MD Dr. Winfrey introduces a core theme: Lyme is not only an infection—it often behaves like a neuroimmune illness. Key takeaways: The brain is a high-energy, high-immune-demand organ, uniquely vulnerable to infection-driven inflammation and toxicity. Lyme can disrupt brain function through: Blood flow issues Synaptic dysfunction Myelin damage Network-level disruption, not just “neurotransmitters” He describes brain function through networks that Lyme can destabilize: Default Mode Network (internal reflection) Salience Network (switching between networks) Central Executive Network (planning/organization) Action Network (execution) Autonomic Network (regulation) Limbic Network (threat/fear response) The result: patients often describe “brain shutdown,” confusion, cognitive impairment, and even dementia-like symptoms. A major reframing: Emotions are not “non-physical.” They are measurable physiological states. Lyme-driven nervous system injury can create emotional disturbance because the biology is disturbed. Segment 2: Poly-microbial Infection, Fight-or-Flight, and the Belief-Healing Loop Winfrey + Rich Discussion Rich frames humans as spiritual, emotional, and physical beings, and asks how chronic infection impacts both body and emotional resilience. Key points: Lyme can cross the blood-brain barrier and affect virtually any organ system. The nervous system becomes a “central battleground,” and measurement is hard because nervous system dysfunction isn't captured well by simple bloodwork. Rich and Dr. Winfrey explore how illness disrupts perception, decision-making, and our ability to interpret the world—especially when gut function and intuition feel “offline.” The healing paradox: Chronic stress and “fighting your way to healing” can backfire. Dr. Winfrey emphasizes that healing requires a parasympathetic state—rest, digest, repair—and that this often involves acceptance, surrender, trust, and safety. Segment 3: The State of Testing—Why So Many Patients Test Negative Nicole Bell (Galaxy Diagnostics) Nicole shares her personal motivation and professional mission: testing determines treatment, reimbursement, and belief—and too many patients are failed by existing tools. Indirect testing (antibody testing): The standard approach relies on antibodies—meaning it depends on the immune system behaving predictably. But Lyme and other stealth pathogens evade and suppress immune responses. Even in controlled research models, two infected subjects can show completely different antibody patterns. Immunosuppression (illness severity, medications like steroids, immune dysregulation) can reduce antibody reliability. Direct testing (pathogen detection):Nicole contrasts Lyme testing with illnesses like COVID—where you use tests that look for the pathogen itself (PCR/antigen), not just antibodies. Why direct detection is hard in Lyme: Pathogens can be low abundance They can be tissue-sequestered Sampling matters Why urine can matter for Lyme: Lyme may not stay in blood, but it can shed proteins/antigens that filter into urine. Galaxy's approach includes methods to capture, concentrate, and detect those markers. New diagnostics focus: Genus-level screening for the “3Bs” (Borrelia, Bartonella, Babesia) Reducing guessing when symptoms overlap and co-infections “masquerade” as each other Segment 4: Immune Dysfunction, Mast Cells, and Why Antibody Testing Can Go Haywire Tania Dempsey, MD (AIM Center for Personalized Medicine) Dr. Dempsey explains the immune system through two major branches: Innate immune system (fast, primitive defense) Adaptive immune system (antibodies, longer-term response) Mast cells as first responders: Mast cells detect “danger” and release inflammatory mediators (histamine and many others). In chronic infection, mast cells can remain persistently activated, releasing hundreds of inflammatory compounds. Why antibody tests fail (two patterns): Immune suppression → insufficient antibody production → false negatives Immune chaos → excessive, inappropriate antibody production → confusing positives - Positive Lyme bands “everywhere” - Positive autoantibodies without classic autoimmune disease patterns - “Everything looks positive” because signaling is dysfunctional Her central philosophy:It's not only about killing the bug. It's about fixing immune regulation so the body can actually clear or control infection. She also names the broader context: modern toxic load (mold, plastics, pesticides, “forever chemicals”) primes the immune system into dysregulation before infections even arrive. Segment 5: Advanced Immune-Modulating Tools Therapeutic Plasma Exchange + SOT Dr. Dempsey discusses therapies she's excited about, especially for complex, stuck cases: Therapeutic Plasma Exchange (TPE / plasmapheresis): Removes plasma (where antibodies, inflammatory mediators, and “garbage” accumulate) Replaces with albumin (and sometimes IVIG) Concept: reduce inflammatory burden + toxic load to reset the terrain SOT (Supportive Oligonucleotide Technique): Molecular targeted approach designed to reduce replication of specific pathogens More targeted than “wide-net” antimicrobial approaches Used strategically after lowering inflammatory/toxic burden She emphasizes: not for everyone, not a universal cure—but promising enough to merit formal publication. Segment 6: GLP-1 Agonists and Mast Cell Stabilization “Brain-melt” moment, revisited Dr. Dempsey explains why drugs commonly known for diabetes/weight loss may have immune benefits: Mast cells have receptors for GLP and GIP hormones Patients showed improvements beyond weight: cognitive function, inflammation, immune stability She describes: Semaglutide (Ozempic/Wegovy) Tirzepatide (Mounjaro/Zepbound) Emerging triple agonists (GLP-1/GIP/glucagon pathways) Her clinical approach has moved these agents earlier in care plans for immune stabilization in select cases. Segment 7: Cellular Healing, Mitochondria, and the Terrain Melanie Stein, ND Dr. Stein brings it home: healing often stalls when we focus only on killing pathogens, but don't repair the cellular damage. Core concepts: Lyme damages cell membranes, disrupting what goes in/out and how cells communicate. It contributes to mitochondrial dysfunction, reducing ATP (energy currency). If cells stay in “alarm mode,” healing remains blocked. Cell membrane therapy and terrain support: IV and oral lipid support (phospholipids, phosphatidylcholine, omega fatty acids) Personalized support based on lipidomic patterns Supportive therapies to reduce oxidative stress and “toxic fats” Focus on signaling safety to the body—so repair can resume Cell Danger Response:A key theme: even after infections reduce, the body may remain stuck in a persistent defense state, requiring cellular and nervous system support to exit “danger mode.” Regulation Before Eradication Panel Reflection Round As the panel closes, several themes converge: Limbic system + autonomic nervous system regulation is foundational “Regulation becomes before eradication” Healing requires safety, predictability, and nervous system calm Chronic illness can block our ability to connect—especially in relationships—because survival physiology dominates Dr. Dempsey adds that limbic retraining / nervous system reset is often the first step she starts with in her practice. Question and Answer Highlights Lyme and Cancer? The panel notes emerging signals connecting tick-borne illness and certain cancers, but emphasizes that more research is needed to determine causality. Herniated discs, connective tissue, and chronic infection The discussion highlights potential links through: connective tissue disruption collagen damage mast cell mediators (enzymes that affect tissue integrity) infection-driven inflammation Cross-reactive antibody results (example: Brucella) The group explains how antibody testing can produce confusing results due to immune dysregulation and cross-reactivity—another reason why interpretation and test methodology matter. Nasal testing / sinus terrain While not a mainstream Lyme diagnostic route, the panel references nasal/sinus colonization (especially with mold-related or chronic inflammatory patterns) as a terrain factor that can influence recovery. Resources Mentioned Center for Lyme Action – State of Lyme Disease Research paper (Nicole Bell collaboration) ILADS Provider Search International Lyme and Associated Diseases Educational Foundation (ILADEF) Donations (supports education and clinician training) Final Message to Listeners This episode is a reminder that Lyme disease and infection-associated chronic illness are not one-dimensional problems. The path forward often requires: better diagnostics immune regulation nervous system support cellular repair personalized care and hope that the body can recover when the right puzzle pieces come together
JHLT: The Podcast kicks off April with a discussion of the paper, "Lung Cancer After Lung Transplantation: Early Detection and Curative Surgery Drive Long-Term Survival," which appears in the April issue of JHLT. Senior author Pauline Pradère, MD, of Hôpital Marie Lannelongue in Paris, joins the episode to talk about the paper. The conversation includes discussion of: The overall survival of patients who develop lung cancer after lung transplant—and the key differences between the cohort of patients who developed cancer versus the patients who did not Managing lung cancer in transplant recipients Immunosuppression in these patients, and other potential changes to clinical practice derived from the study For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.
In this week's episode we interview Joseph Parambil, MD, staff member in the department of pulmonary, allergy and critical care medicine at Cleveland Clinic, about the current challenges of interstitial lung disease, or ILD. · Intro by Adam J. Brown, MD 0:12 · Welcome back Joseph Parambil, MD 0:32 · But first, some medical history on ILD 1:04 · ILD vs. IPF 2:26 · A quick aside into silicosis and bleomycin 4:27 · Trying to describe pulmonary fibrosis 5:23 · The different types of ILD 9:44 · Finding a slow progression of disease and autoimmune conditions 10:59 · Pulmonary fibrosis diagnoses in 1963 14:41 · The modern era of ILD 16:22 · Nonspecific interstitial pneumonia 20:12 · Handing things over to Dr. Parambil 23:01 · Helping rheumatologists understand ILD/The alphabet soup 24:34 · The shift from biopsies and using immunosuppression 33:07 · Is the workup similar for UIP and NSIP? 35:26 · Is there a standard protocol for workup in terms of serologies? 36:30 · The danger of choosing the wrong treatment 38:43 · Immunosuppression in patients with pulmonary hypertension and ILD 40:52 · UIP and ANCA vasculitis 42:12 · Compared to ten years ago, how are we doing with treatments? 43:10 · Where are we with lung transplants? 50:49 · Looking at hematopoietic stem cell transplants 53:24 · The importance of early diagnosis 54:14 · Antifibrotic medicines 56:15 · Chronic and acute interstitial lung diseases 58:41 · Thank you, Dr. Parambil 1:03:54 · A conclusion from Dr. Brown 1:04:20 · Thank you for listening 1:04:55 We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum. Joseph Parambil, MD, is a staff member in the Respiratory Institute and the director of the HHT Center of Excellence and the Vascular Anomalies Center at the Cleveland Clinic. He is associate professor of medicine at Cleveland Clinic's Lerner College of Medicine. He is certified by the American Board of Internal Medicine with additional specialty certification in pulmonary medicine and critical care medicine. References: Homolka J. CMAJ. 1987;PMID:3315158 Liebow A, et al. : "Frontiers of Pulmonary Radiology." The interstitial pneumonias, pp. 102-141. 1969. Grune & Stratton. Liebow A, et al. Calif Med. 1969;PMID:PMC1501512 Noble PW, et al. Am J Respir Cell Mol Biol. 2005;doi:10.1165/rcmb.F301 Scadding JG, et al. Thorax. 1967;doi:10.1136/thx.22.4.291 Disclosures: Brown and Parambil report no relevant financial disclosures.
Vitamin B12 for hand-foot syndrome -Device-assisted delivery for fillers -Sirolimus for infantile hemangiomas -HPV + immunosuppression = bad -Jarisch-Herxheimer-like reaction to griseofulvin -Check out Luke's Urticaria CME experience! aaaaicsu.gathered.com/invite/KQe1wPZbJY Learn more about the U of U Dermatology ECHO model! physicians.utah.edu/echo/dermatology-primarycare Want to donate to the cause? Do so here! Donate to the podcast: uofuhealth.org/dermasphere Check out our video content on YouTube: www.youtube.com/@dermaspherepodcast and VuMedi!: www.vumedi.com/channel/dermasphere/ The University of Utah's Dermatology ECHO: physicians.utah.edu/echo/dermatology-primarycare - Connect with us! - Web: dermaspherepodcast.com/ - Twitter: @DermaspherePC - Instagram: dermaspherepodcast - Facebook: www.facebook.com/DermaspherePodcast/ - Check out Luke and Michelle's other podcast, SkinCast! healthcare.utah.edu/dermatology/skincast/ Luke and Michelle report no significant conflicts of interest… BUT check out our friends at: - Kikoxp.com (a social platform for doctors to share knowledge) - www.levelex.com/games/top-derm (A free dermatology game to learn more dermatology!
Today we're joined by Sean MacDonald, CEO of Kainova Therapeutics. With more than twenty years of biotech leadership and deep expertise in strategy and development, Sean is guiding the company through an exciting new chapter.We'll dive into Kainova's innovative GPCR-modulating platform, its promising pipeline, the science behind reversing tumor immunosuppression and targeting inflammation, and the reasons behind the recent rebrand from Domain Therapeutics to Kainova Therapeutics.We'll also be taking a look at the broader oncology landscape—what's hot, who's investing big, and where the biggest opportunities and challenges lie.01:09 – Meet Sean Macdonald05:40 – Kainova's GPCR platform and therapeutic focus08:57 – The story and meaning behind the Kainova rebrand10:25 – Series B funding and pipeline programs16:43 – Exciting trends and innovations in oncology29:17 – Upcoming milestones and future plansInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: GPCR therapies: Eight promising biotechs hacking the cell signaling pathwayEpisode 182: Building a smart oncology pipeline with Cumulus OncologyEpisode 34: eClinical Solutions, GPCR Therapeutics, Orbsen Therapeutics
Dr. Edmund Tsui and author Dr. Douglas A. Jabs discuss the results of the ADVISE Trial, designed to compare adalimumab to conventional immunosuppressive drugs for the treatment of non-infectious intermediate, posterior, and panuveitides. From Dr. Jab's Ophthalmology article, "Adalimumab vs. Conventional Immunosuppression for Uveitis (ADVISE) Trial." Adalimumab vs. Conventional Immunosuppression for Uveitis (ADVISE) Trial. Jabs, Douglas A. et al. Ophthalmology. In press. Sign up for the next Ophthalmology Journal Virtual Club on February 25, 2026, at https://store.aao.org/ophthalmology-virtual-journal-club.html
In this mind-expanding episode, Darin sits down with Dani Fontaine — researcher, practitioner, and expert on the human body's forgotten communication system: the endocannabinoid system. They unravel how this network regulates everything from mood and sleep to pain and consciousness — and why it was deliberately scrubbed from mainstream medical education. Dani reveals how cannabinoids, light, sound, and nature all communicate with our body's receptor fields — shaping the way we feel, heal, and perceive the world. Together they explore the profound spiritual and scientific implications of this hidden system, and how it connects us back to balance, nature, and truth. What You'll Learn 00:00:00 - Welcome to the SuperLife Podcast 00:00:32 - Sponsor: Energy Bits 00:01:52 - Introducing Guest Danny Fontaine: Cannabis Pioneer and Plant Medicine Healer 00:04:54 - Deep Dive: What is the Endocannabinoid System (ECS)? 00:06:30 - ECS: The Homeostasis and Retrograde Signaling System 00:09:20 - ECS as a Receptive System for Subtle Energies and Environment 00:10:23 - Endocannabinoid System Toning (X-Tone) 00:12:58 - When the ECS Gets Worn and Depleted 00:16:34 - ECS Receptors on Every Cell, Fascia, and Neural Makeup 00:19:14 - How the ECS Breaks Down: The Impact of False Light 00:22:11 - The ECS and Non-Photon Rich Food 00:23:40 - Modulating the ECS Through the Six Senses (Touch and Breath) 00:24:38 - Mitochondria and ECS Receptors (MTK, CB1) 00:25:14 - Endogenous ECS and the Need for Proper Nutrients 00:27:11 - Cannabis as our Phyto Twin: The Plant Factor 00:27:57 - THC and the Suppression of Anandamide (Bliss Molecule) 00:31:44 - Sponsor: Fatty 15 00:35:25 - The Vast Amount of ECS Research & Medical Suppression 00:38:27 - Cannabinoids, Pain, and Individual Assessment 00:40:29 - Modulating ECS with Nature: Terpenes like Pinene 00:42:51 - Olfactory System as the Most Sophisticated Input 00:47:03 - ECS as the "Microscope Moment" for Health 00:48:23 - Pinene, CB1, and TRP Receptors in Pain Management 00:50:39 - The ECS, Collagen, and Hyaluronic Acid Fluctuation 00:51:44 - Working with the ECS for Faster Results (Cancer and Genetic Mutations) 00:55:06 - Sponsor: SuperLife Patreon 00:56:39 - Measuring the ECS with Bio-Field Technology 00:57:29 - The Danger of THC Stacking and Immunosuppression 00:59:30 - Overwhelmed Cells and Fake Inputs 01:00:12 - Hemp as a Homeostasis Plant for the Planet (Soil Remediation/Carbon) 01:02:06 - ECS Strength in Animals vs. Humans 01:04:08 - Why Cannabis and Hemp Were Suppressed 01:07:07 - The Historical Use of Cannabis in Medicine 01:08:12 - Hemp's Nutritional Profile (Amino Acids and Omegas) 01:09:37 - Ayahuasca, Receptor Overexpression, and Looping 01:13:33 - Importance of ECS Knowledge and Application 01:14:58 - Exercise, Anandamide, and ECS Toning 01:15:22 - Cold Plunge and Shocking the ECS and Hormones 01:17:16 - Takeaways: Light, Movement, Sound, and Breath 01:21:41 - ECS: The Main Signaling and Communication System 01:23:28 - Final Thoughts: ECS as the Conduit to Self and Spirit Thank You to Our Sponsors: Fatty15: Get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/DARIN and using code DARIN at checkout. EnergyBits: Get 20% off your entire order by going to https://energybits.com/ and using code DARIN at checkout. Find More from Dani Fontaine Instagram: @danifontaine Website: danifontaine.com Products: Try Dani's Nature Root Connect with Darin Olien: Website: darinolien.com Instagram: @darinolien Book: Fatal Conveniences Platform & Products: superlife.com Key Takeaway “Your endocannabinoid system isn't just a biology lesson — it's a bridge between your body and the universe. When you feed it light, breath, and truth, you remember what balance actually feels like.”
This week we review a recent multicenter, randomized trial pitting 2 different immunosuppressive therapeutic approaches against each other. How did a novel approach of everolimus + low dose tacrolimus compare to more standard MMF + standard, higher dose tacrolimus in avoidance of major adverse transplant events or complications? How did this first ever prospective trial in the pediatric heart transplantation world start and how difficult was it to perform in the absence of corporate or NIH support? Why can these data help inform FDA labelling for this novel approach and why is this important? Dr. Kevin Daly of Boston Children's Hospital shares his deep insights into this work this week!DOI: 10.1001/jama.2025.14338
Vidcast: https://www.instagram.com/p/DN06krQ2q-f/Immunologists at the Medical University of South Carolina have found a way to direct the body's immune system to censor itself permitting transplanted human organs to flourish with medicinal immunosuppression. Their study appeared recently in Frontiers in Immunology.The investigators genetically engineered so-called regulatory T cells, Treg lymphocytes, to selectively destroy those B lymphocytes programmed to produce the antibodies that attack transplanted organs. This self-immunosuppression could extend the life of transplanted organs and permit so-called presensitized patients with pre-existing B lymphocytes ready to churn out anti-organ antibodies an opportunity for successful transplantation. Let's hope clinical trials demonstrate the utility of this approach.https://www.news-medical.net/news/20250817/Genetically-engineered-immune-cells-show-promise-for-preventing-organ-rejection.aspxhttps://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1601385/full#transplantation #immunosuppression #Treg #antibodies #presensitized
Dr. Hoffman continues his conversation with Dr. Robert Silverman, author of "Immune Reboot: Maximizing Immunity, Restoring Gut Health, and Optimizing Vitality."
Dr. Robert Silverman, author of "Immune Reboot: Maximizing Immunity, Restoring Gut Health, and Optimizing Vitality," provides a comprehensive primer on the immune system. He explains how lifestyle factors—diet, sleep, exercise, and stress—impact immune resilience. He offers specific protocols for optimizing resistance to Covid, what to do if you come down with it, and how to treat Long Covid, as well as how to prepare for vaccines.
In this episode of the Xtalks Life Science Podcast, host Ayesha Rashid speaks with Rob Armstrong, PhD, CEO of Artax Biopharma, a company pioneering a novel class of oral small molecule drugs known as Nck modulators to treat autoimmune diseases. Unlike traditional therapies that suppress the immune system, Artax's approach aims to restore immune balance by modulating T cell receptor signaling. Dr. Armstrong shares insights into the company's recent clinical progress, including positive Phase IIa results in psoriasis and promising preclinical data in atopic dermatitis, and what these milestones mean for the broader autoimmune treatment landscape. With more than 20 years of leadership in biopharmaceutical R&D, Dr. Armstrong previously served as CEO, board member and co-founder of Boston Pharmaceuticals, led small molecule R&D at Amgen and held senior executive roles at Eli Lilly, including Vice President of Global Medicinal Chemistry. Dr. Armstrong was Chairman of the Board of Artax Biopharma until January 2024, when he was appointed as the company's CEO. Prior to working in industry, Dr. Armstrong was a tenured Professor of Chemistry and Biochemistry at the University of California at Los Angeles (UCLA). Dr. Armstrong received his Bachelor of Science (BS) in chemistry at University of California San Diego (UCSD), PhD in chemistry at California State University (CSU) and was an NIH postdoctoral fellow at Harvard. Rob is an advisor to Gelesis and serves on the board of directors of early-stage biotechnology companies Curza Therapeutics, Cloud Pharmaceuticals and Entrega Bio. Tune into the episode to hear Dr. Armstrong discuss the promise of Nck modulators and breakthroughs in autoimmune therapies. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured
Vidcast: https://www.instagram.com/p/DNd6KltPeD_/Transplantation immuno-geneticists at Sweden's Uppsala University Hospital have successfully used gene editing to modify human pancreatic islet cells such that these transplants are more histocompatible, survive longer, and function better. Their single patient case report appeared in a recent issues of the New England Journal of Medicine.The recipient is a 42-year-old male juvenile-onset insulin-dependent diabetic. The researchers utilized CRISPR-Cas12b gene editing technology to delete genes that code for incompatible cell surface antigens while adding genes coding for protective antigens thereby making the donor pancreatic cells invisible to the recipient's immune system.Over a 12-week period, the limited number of gene-edited islet cells available for transplantation were able to reduce but not totally eliminate the recipients insulin requirement. This proved the viability and functional integrity of the transplanted islet cells suggesting that transplantation of a larger complement of islet cells could provide a recipient's total insulin requirement therapy curing diabetes without the need for ongoing immunosuppression with its often toxic side effects.https://medicalxpress.com/news/2025-08-gene-islet-transplant-human-functional.htmlhttps://www.nejm.org/doi/10.1056/NEJMoa2503822#diabetes #insulin #isletcells #transplantation #geneediting #immunosuppression
Welcome back to Ditch the Lab Coat, the podcast where we break down the fascinating world of medicine with a blend of scientific skepticism and real-world insight. In today's episode, we dive deep into the mysteries of the vagus nerve—a nerve so ancient and essential, it's been called the “conductor” in the symphony of human physiology.Join host Dr. Mark Bonta as he sits down with Dr. Kevin Tracey, neurosurgeon, president and CEO of the Feinstein Institutes for Medical Research, and a pioneer in the world of bioelectronic medicine. Dr. Tracey's breakthrough research has shown us that the vagus nerve is far more than just a conduit for signals—it's a key player in managing inflammation, regulating our immune system, and maybe even shaping the future of medicine.In this conversation, you'll explore the mind-bending complexity of the nervous system, discover how cutting-edge science is redefining how we treat diseases like rheumatoid arthritis and long Covid, and learn how a tiny chip implanted in the neck might one day replace whole classes of immune-suppressing drugs. Dr. Tracey shares metaphors, straight talk about medical myths, and a vision for a future where reprogramming the body's reflexes could offer relief to millions.Get ready for a journey that's equal parts awe-inspiring and practical, as we unpack the true potential (and real-world considerations) of harnessing the vagus nerve's power. Whether you're a healthcare professional, a science nerd, or just someone searching for new answers, this episode invites you to see medicine in a whole new way. Resources : ( https://feinstein.northwell.edu/ )Episode HighlightsVagus Nerve Complexity Unveiled — We're only scratching the surface of understanding the vagus nerve's vast, intricate network and its essential bodily roles.Inflammation: Friend and Foe — Inflammation is vital short-term, but when uncontrolled, it's destructive and underlies many autoimmune and chronic diseases.Nervous-Immune System Interplay — The nervous and immune systems communicate reflexively, with nerves directly capable of controlling immune and inflammatory responses.Bioelectronic Treatments Emerge — Vagus nerve stimulation—via implanted chips—shows promise for conditions like rheumatoid arthritis without full-body immunosuppression risks.Individualized Nerve Fiber Functions — Each of the 200,000 vagus fibers controls specific functions, forming a body-wide symphony of precision responses.Not All Self-Help Fits — Lifestyle hacks can support vagus health, but serious disease often requires targeted nerve stimulation, not general wellness.Caution Against Online Misinformation — Vagus nerve advice online is often oversimplified or inaccurate; nuance and scientific backing are essential.Lifestyle Still Matters — Balanced diet, sleep, exercise, and community all help regulate vagus nerve tone and reduce chronic stress.Future Disease Applications Possible — Vagus stimulation may treat IBD, MS, and neurodegenerative or psychiatric conditions as research evolves.Episode Timestamps6:25 — Exploring Nervous System Complexity9:08 — Vagus Nerve Controls Inflammation11:05 — Vagus Nerve: Brain Signals Control Inflammation15:45 — Nervous System's Role in Immunity20:43 — Understanding Your Vagus Nerves23:25 — Vagus Nerve Health and Research25:12 — Vagus Nerve Stimulation Insights29:36 — Vagus Nerve Stimulator: Inflammation Therapy32:13 — Neurotransmitter Effects on Cytokine Production38:22 — Minimizing Nerve Damage in Surgery39:30 — Vagus Nerve Stimulation Benefits43:42 — Exploring Vagus Nerve Mysteries46:42 — Vagus Nerve Stimulation for Autoimmune Diseases50:52 — Cold Plunges & Bioelectrical Future DISCLAMER >>>>>> The Ditch Lab Coat podcast serves solely for general informational purposes and does not serve as a substitute for professional medical services such as medicine or nursing. It does not establish a doctor/patient relationship, and the use of information from the podcast or linked materials is at the user's own risk. The content does not aim to replace professional medical advice, diagnosis, or treatment, and users should promptly seek guidance from healthcare professionals for any medical conditions. >>>>>> The expressed opinions belong solely to the hosts and guests, and they do not necessarily reflect the views or opinions of the Hospitals, Clinics, Universities, or any other organization associated with the host or guests. Disclosures: Ditch The Lab Coat podcast is produced by (Podkind.co) and is independent of Dr. Bonta's teaching and research roles at McMaster University, Temerty Faculty of Medicine and Queens University.
Beyond the Digest are bonus episodes to the DermSurgery Digest that include reviews of interesting and relevant articles from the Journal of the American Academy of Dermatology (JAAD), British Journal of Dermatology (BJD) and JAMA Dermatology.Articles featured in this episode include: “Part 1: Management of antithrombotic medications in dermatologic surgery.” JAAD + “Part 2: Management of intraoperative and perioperative bleeding.” JAAD“5-fluorouracil 5% cream for squamous cell carcinoma in situ: Factors impacting treatment response.” JAAD“Risk of Death Due to Melanoma and Other Causes in Patients With Thin Cutaneous Melanomas.” JAMA Dermatology “Improved disease-specific survival in lentigo maligna treated with Mohs surgery over wide local excision: a retrospective cohort analysis.” BJD, research letter + “Surviving by a margin: Mohs outperforms wide local excision for lentigo maligna.” BJD, commentary on the research letter“Thin and in situ melanomas of unfavorable prognosis: A retrospective observational analysis of local recurrence, metastasis, and death in early-stage disease.” JAAD“Merkel Cell Carcinoma and Immunosuppression, UV Radiation, and Merkel Cell Polyomavirus.” JAMA Dermatology“Reduction of masseter muscle prominence after treatment with onabotulinumtoxinA: Primary results from a randomized phase 2 study.” JAAD“Improvement of platysma prominence with onabotulinumtoxinA: Safety and efficacy results from a randomized, double-blinded, placebo-controlled phase 3 trial.” JAAD Beyond the Digest Contributors include Naomi Lawrence, MD, Dermatologic Surgery Digital Content Editor; Yesul Kim, MD, Beyond the Digest Co-host; Ami Greene, MD; Tara Jennings, MD; Payvand Kamrani, DO; Sydney Proffer, MD; Kathryn Shahwan, MD; and Yssra Soliman, MD. Your feedback is encouraged. Please contact communicationstaff@asds.net.
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SVZ865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2026.Improving Kidney Transplant Access and Equity With Innovative Immunosuppression Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SVZ865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2026.Improving Kidney Transplant Access and Equity With Innovative Immunosuppression Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SVZ865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2026.Improving Kidney Transplant Access and Equity With Innovative Immunosuppression Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SVZ865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2026.Improving Kidney Transplant Access and Equity With Innovative Immunosuppression Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SVZ865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2026.Improving Kidney Transplant Access and Equity With Innovative Immunosuppression Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SVZ865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2026.Improving Kidney Transplant Access and Equity With Innovative Immunosuppression Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SVZ865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2026.Improving Kidney Transplant Access and Equity With Innovative Immunosuppression Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
In this episode of "Ask the Expert," Dr. Eoin Flanagan joined Dr. GG deFiebre of SRNA. Dr. Flanagan explained how immunosuppressive medications impact the immune system and the efficacy of vaccines [00:02:45]. He discussed the primary concerns and risks of vaccinating individuals on these therapies, including avoiding live vaccines and the need for additional booster doses [00:04:52]. Dr. Flanagan also talked about the recommended vaccines for those with conditions like NMOSD or MOGAD, and underlined the importance of getting vaccinated to prevent severe infections [00:09:40]. He addressed common misconceptions and emphasized the role of healthcare providers in educating and supporting their patients regarding vaccinations [00:15:32].Eoin Flanagan, MB, BCh is a Professor of Neurology and Consultant in the departments of Neurology and Laboratory Medicine and Pathology at the Mayo Clinic (Rochester, MN). He completed his medical school training at University College Dublin in Ireland in 2005. He did a medical residency in Ireland and then completed neurology residency, fellowships in neuroimmunology and a masters in clinical and translational science at Mayo Clinic (Rochester, MN). He works in the Autoimmune Neurology and Multiple Sclerosis Clinics and the Neuroimmunology Laboratory at the Mayo Clinic. His clinical expertise and research are focused on inflammatory myelopathies and their imaging patterns, myelin oligodendrocyte glycoprotein (MOG) antibody associated disorder, neuromyelitis optica spectrum disorders, autoimmune encephalitis, paraneoplastic neurologic disorders, and multiple sclerosis. He is principal investigator on an NIH RO1 grant studying MOG antibody associated disorder.00:00 Introduction 00:47 Understanding Immunosuppressants and Vaccines01:28 Primary Concerns with Vaccinating Immunosuppressed Patients02:30 Recommended Vaccines for Immunosuppressed Patients07:11 Timing and Effectiveness of Vaccinations08:21 Measuring Vaccine Response09:24 Addressing Missed Doses and Safety Considerations16:41 Public Health Implications and Patient Advocacy17:56 Advice for Vaccine-Hesitant Patients19:06 Healthcare Providers' Role in Vaccination20:03 Conclusion and Final Thoughts
In this episode, we meet up with Josh Conklin, a seasoned bone marrow transplant (BMT) nurse at the University of Michigan Hospital, to explore his experiences, insights, and tips for managing chronic graft-versus-host disease (GVHD). With 11 years of inpatient experience, Josh offers a comprehensive view of the challenges and triumphs in caring for patients undergoing BMT.Josh explains that his primary role involves guiding patients through the most critical stages of their transplant journey, from chemotherapy conditioning to the stem cell infusion and the vulnerable recovery period afterward. He emphasizes the delicate balance required in managing GVHD, a condition that plays a dual role: while some GvHD is beneficial in suppressing cancer recurrence (graft-versus-leukemia effect), too much can lead to severe complications.Long-term immunosuppression is a cornerstone of GVHD management. Josh highlights the reliance on drugs like tacrolimus and, when necessary, steroids. However, we note the adverse effects of prolonged steroid use, such as muscle wasting, infections, and physical deconditioning. Emerging monoclonal antibody therapies are offering new hope, aiming to reduce these side effects.The discussion also sheds light on the psychological toll of repeated hospitalizations and the role caregivers play in patient success. Josh describes caregivers as essential for monitoring symptoms, administering medications, and providing emotional support. However, he acknowledges the significant strain caregiving can impose, especially during the critical first 100 days post-transplant when patients are highly vulnerable.Josh shares stories of resilience and purpose among his patients, underscoring the importance of a positive outlook and having something meaningful to strive for. He reflects on the impact of a strong support system, whether it's family, friends, or peer mentorship programs, in helping patients navigate their “new normal.” Despite the challenges, Josh finds inspiration in his patients' ability to find joy and purpose, even in difficult circumstances. He shares his experience with one woman in particular.This heartfelt conversation highlights the physical, emotional, and relational dynamics of BMT care, offering a glimpse into the profound impact of dedicated healthcare professionals like Josh.More:GVHD Alliance: https://www.gvhdalliance.orgLink to LLS free Nutrition Consultations: https://www.lls.org/managing-your-cancer/food-and-nutritionThank you to our sponsors. This season is supported by a healthcare contribution from Sanofi https://www.sanofi.com/ National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd
This Real Science Exchange podcast episode was recorded during a webinar from Balchem's Real Science Lecture Series. You can find it at balchem.com/realscience.Feeding rumen-protected choline in early lactation has consistently increased milk yield and energy-corrected milk yield, which is more pronounced when cows are fed diets low in metabolizable methionine. Choline feeding also increases milk fat and protein yield, minimizes body condition loss in early lactation, and reduces postpartum disease incidence. Dr. McFadden presents three topics about choline biology in the dairy cow. (01:45)Why should we consider fatty acid feeding when feeding methyl donors like choline and methionine?Choline degradation in the rumen and small intestine, focusing on the role of triethylamine oxide Why should we consider lysophosphatidylcholine as an immunomodulator in fresh cows and preweaning calves?Fatty acid nutrition to optimize methyl donor efficiency. (4:02)Fatty liver is a concern for fresh cows because of its relationship with ketosis, poor fertility and compromised milk production. Cows with fatty liver exhibit low circulating concentrations of phosphatidylcholine, which is a component of very low-density lipoproteins (VLDL) that transport triglycerides out of the liver. Feeding rumen-protected choline lowers liver triglyceride deposition by supporting the synthesis of phosphatidylcholine and thus, VLDL. Dr. McFadden goes on to explain the two different pathways for phosphatidylcholine in the liver and how those interact with fatty acid metabolism. He describes several experiments that have investigated how rumen-protected choline and supplemental fatty acids interact in lactating cows. Low phosphatidylcholine supply is a key feature of fatty liver in dairy cows, likely due to low polyunsaturated fatty acid (PUFA) and low choline supplies. Delivery of post-ruminal PUFA may support phosphatidylcholine synthesis with accompanying improvements in insulin sensitivity, body condition maintenance, and inflammation, but interactions with dietary fatty acid digestibility should be considered. Dr. McFadden gives a list of considerations for fresh cow diets incorporating fat and choline supplementation. Gastrointestinal choline degradation and trimethylamine N-oxide (TMAO) (16:58)Unprotected choline is almost totally degraded in the rumen. Microbes convert choline into trimethylamine (TMA) which is then converted to TMAO in the liver. Rumen-protected choline allows for a large proportion of choline to reach the small intestine intact. However, research shows that choline can also be degraded by microbes in the small intestine in the same pathway, limiting choline bioavailability. Plasma TMAO accumulation is associated with non-alcoholic fatty liver disease, inflammation, insulin resistance, obesity, oxidative stress, and cardiovascular disease in rodent and human models. Little research was available regarding if the relationship between TMAO and poor health was causative or just associative. Dr. McFadden's lab infused cows intravenously with TMAO and found that TMAO did not modify milk production or glucose tolerance in early lactation cows. TMAO does not appear to influence energy metabolism or health in early lactation cows. Choline is subject to both ruminal and lower-gut degradation to TMA, and that influence on choline bioavailability needs to be defined. Data in non-ruminants suggests that unsaturated fatty acid feeding can shift the gut microbes to slow TMA formation. Lysophosphatidylcholine and immunomodulation (28:45)Dr. McFadden gives an overview of neutrophil activation and the oxidative burst that contributes to pathogen killing. The ability to elicit the oxidative burst is diminished in pre-weaned calves and transition cows. When cows were given endotoxin to cause an immune response, circulating lysophosphatidylcholine was decreased. In rodent models, lysophosphatidylcholine promotes the oxidative burst and suppresses long-term inflammation in response to bacterial infection. Dr. McFadden cultured neutrophils from pre-weaned calves with lysophosphatidylcholine and observed an enhanced oxidative burst.Immunosuppression is characterized by low circulating lysophosphatidylcholine concentrations in dairy cows. In vitro data suggests lysophosphatidylcholine can activate neutrophils, and rumen-protected choline increases circulating lysophosphatidylcholine. Future research is likely to define an immunomodulatory role for choline. Dr. McFadden takes questions from the webinar audience. (38:07)Please subscribe and share with your industry friends to invite more people to join us at the Real Science Exchange virtual pub table. If you want one of our Real Science Exchange t-shirts, screenshot your rating, review, or subscription, and email a picture to anh.marketing@balchem.com. Include your size and mailing address, and we'll mail you a shirt.
On the second December episode of JHLT: The Podcast, the Digital Media Editors explore another paper from the December issue of JHLT, entitled “Long-term follow-up of the randomized, prospective Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance (SCHEDULE) trial.” First author Entela Bollano, MD, PhD, and senior author Niklas Bergh, MD, PhD, both from the Sahlgrenska University Hospital in Sweden, join the podcast to discuss their work. You'll hear about: Past outcomes of the SCHEDULE trial, including reduced CAV in patients on everolimus over patients on CNIs How this study filled the need for long-term follow up on randomized studies on immunosuppression Limitations of the study, and what additional follow up might teach us For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Lung clinicians: if you haven't yet tuned in for the first episode from this month, check it out! The paper discusses the effects of pollution post lung transplantation. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.
References Nature 2024.volume 635, pages 1010–1018 Front. Immunol. 2024. Sec. Multiple Sclerosis and Neuroimmunology Volume 15. J Immunol 2017. 199 (3) 874-884. Hunter-Garcia.1970 "Cumberland Blues" on Workingman's Dead https://open.spotify.com/track/2op5szd2IY8bOPzumqmFY3?si=8e3061b4559a4a31 Mozart. WA. 1791. Clarinet Concerto in A K 622 https://open.spotify.com/album/5WZELp7jlJNdS2xgLRknwe?si=ROhHJdu2RWCIpqnL7KXFUg --- Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support
Dennis O. Clegg, Ph.D., discusses treatments for age-related macular degeneration (AMD), a condition that causes vision loss. Clegg explains that while patients often report improved vision after receiving implants, objective tests don't always confirm this. He explores the potential differences in patients' responses based on genetics and disease progression. There is also an ongoing challenge in finding the best ways to reduce immune rejection of these treatments. New trials are underway to test implants in earlier stages of the disease, and researchers are looking at different strategies like localized immunosuppression. Additionally, some studies suggest that secretions from retinal cells may help preserve vision. Overall, there are many open questions, but advances in the field offer hope for better AMD treatments. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39459]
Dennis O. Clegg, Ph.D., discusses treatments for age-related macular degeneration (AMD), a condition that causes vision loss. Clegg explains that while patients often report improved vision after receiving implants, objective tests don't always confirm this. He explores the potential differences in patients' responses based on genetics and disease progression. There is also an ongoing challenge in finding the best ways to reduce immune rejection of these treatments. New trials are underway to test implants in earlier stages of the disease, and researchers are looking at different strategies like localized immunosuppression. Additionally, some studies suggest that secretions from retinal cells may help preserve vision. Overall, there are many open questions, but advances in the field offer hope for better AMD treatments. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39459]
Dennis O. Clegg, Ph.D., discusses treatments for age-related macular degeneration (AMD), a condition that causes vision loss. Clegg explains that while patients often report improved vision after receiving implants, objective tests don't always confirm this. He explores the potential differences in patients' responses based on genetics and disease progression. There is also an ongoing challenge in finding the best ways to reduce immune rejection of these treatments. New trials are underway to test implants in earlier stages of the disease, and researchers are looking at different strategies like localized immunosuppression. Additionally, some studies suggest that secretions from retinal cells may help preserve vision. Overall, there are many open questions, but advances in the field offer hope for better AMD treatments. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39459]
Dennis O. Clegg, Ph.D., discusses treatments for age-related macular degeneration (AMD), a condition that causes vision loss. Clegg explains that while patients often report improved vision after receiving implants, objective tests don't always confirm this. He explores the potential differences in patients' responses based on genetics and disease progression. There is also an ongoing challenge in finding the best ways to reduce immune rejection of these treatments. New trials are underway to test implants in earlier stages of the disease, and researchers are looking at different strategies like localized immunosuppression. Additionally, some studies suggest that secretions from retinal cells may help preserve vision. Overall, there are many open questions, but advances in the field offer hope for better AMD treatments. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39459]
Dennis O. Clegg, Ph.D., discusses treatments for age-related macular degeneration (AMD), a condition that causes vision loss. Clegg explains that while patients often report improved vision after receiving implants, objective tests don't always confirm this. He explores the potential differences in patients' responses based on genetics and disease progression. There is also an ongoing challenge in finding the best ways to reduce immune rejection of these treatments. New trials are underway to test implants in earlier stages of the disease, and researchers are looking at different strategies like localized immunosuppression. Additionally, some studies suggest that secretions from retinal cells may help preserve vision. Overall, there are many open questions, but advances in the field offer hope for better AMD treatments. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39459]
Dennis O. Clegg, Ph.D., discusses treatments for age-related macular degeneration (AMD), a condition that causes vision loss. Clegg explains that while patients often report improved vision after receiving implants, objective tests don't always confirm this. He explores the potential differences in patients' responses based on genetics and disease progression. There is also an ongoing challenge in finding the best ways to reduce immune rejection of these treatments. New trials are underway to test implants in earlier stages of the disease, and researchers are looking at different strategies like localized immunosuppression. Additionally, some studies suggest that secretions from retinal cells may help preserve vision. Overall, there are many open questions, but advances in the field offer hope for better AMD treatments. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39459]
Dennis O. Clegg, Ph.D., discusses treatments for age-related macular degeneration (AMD), a condition that causes vision loss. Clegg explains that while patients often report improved vision after receiving implants, objective tests don't always confirm this. He explores the potential differences in patients' responses based on genetics and disease progression. There is also an ongoing challenge in finding the best ways to reduce immune rejection of these treatments. New trials are underway to test implants in earlier stages of the disease, and researchers are looking at different strategies like localized immunosuppression. Additionally, some studies suggest that secretions from retinal cells may help preserve vision. Overall, there are many open questions, but advances in the field offer hope for better AMD treatments. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39459]
In this episode, we talk with Rachael Sommer, a dedicated mother and caregiver from Cleveland, Ohio. Rachael shares the journey of her daughter Maddie, who was diagnosed with Hepatosplenic T-cell Lymphoma in October 2023, after several months of mysterious symptoms. Treated at Nationwide Children's Hospital in Columbus, Maddie's condition has profoundly impacted their lives.Rachael recounts their initial stay at the Ronald McDonald House post-diagnosis, highlighting the physical and emotional changes Maddie experienced. Maddie's extreme fatigue and breathlessness were particularly challenging, and Rachael emphasizes the importance of adjusting to a "new normal" while staying in constant communication with doctors. Rachael found solace in the Ronald McDonald House's facilities, specifically the fitness room, which helped her manage her own stress.The conversation shifts to the emotional toll on Maddie, who struggled with isolation from friends and the mental burden of not being able to participate in normal activities. Despite the support of friends and thoughtful gestures like sending cards, nothing could replace the physical presence of her peers. Rachael's creativity shone through when she set up a Google camera to allow Maddie to see her cats, Binks and Leon, while they were away.Rachael discusses the importance of recognizing and respecting individual emotional needs. Maddie's withdrawal from activities she once enjoyed, like listening to music, was particularly hard for Rachael, who feared losing her daughter's spirited personality. Eventually, Maddie slowly began to regain her sarcasm and interactions with her younger brother, Ezekiel, signaling a return to her usual self.The financial strain of Maddie's illness is another significant aspect of their journey. Rachael praises the support from various organizations, including Carrie's Cause, Fight Like A Dozer, and the Leukemia & Lymphoma Society, which provided crucial financial aid. This support allowed Rachael to focus on Maddie's care without the added burden of financial stress.Rachael also shares her career transition to consulting, driven by the need for greater flexibility to support her family. Her faith in God has been a cornerstone throughout this journey, providing spiritual strength and community support.Finally, Rachael reflects on the importance of savoring small moments of joy amidst the challenges. She encourages other caregivers to focus on what truly matters, finding moments of normalcy and joy, and maintaining hope and strength for their loved ones.Resources:Nationwide Children's Hospital, Columbus, Ohio: https://www.nationwidechildrens.org/Fight Like a Dozer: https://www.fightlikeadozer.org/Leukemia & Lymphoma Society (LLS): https://lls.org/NMDP (formerly Be The Match): https://bethematch.org/The Bible Recap: https://www.thebiblerecap.com/National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKnbmtLINK YouTube Page can be found by clicking here.Thank you to our sponsors. This season is supported by a healthcare contribution from Sanofi https://www.sanofi.com/ Follow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/
Breast implants are said to be a transformative solution for individuals seeking aesthetic enhancement or breast reconstruction. However, beneath their promise of confidence and beauty lie potential risks that are often overlooked. Breast Implant Illness (BII) underscores the importance of thorough patient education and informed consent, highlighting the complexities and implications associated with implants. That is why there is a need for us to raise more awareness about the realities of breast implant surgery, ensuring that patients are fully informed about the risks and potential consequences. I'm thrilled to introduce our guest for today's episode – Dr. Thomas Chung. We share a similar background in terms of experience and training, which initially intrigued me since he has a clear and insightful understanding of breast implant illness, and we'll delve into that throughout this episode. Plastic surgery career, including microsurgery and breast reconstruction What struck me about Dr. Chung is his extensive experience in microsurgery, a field in which we've both worked. Dr. Chung's journey began with his training in the Navy, where he completed his internship and general surgery residency at Walter Reed, then part of the National Naval Medical Center consortium in DC. During his residency, he managed numerous casualties from conflicts like Fallujah, serving as chief of the trauma service with a daily census of 30 to 40 injured veterans. After finishing his general surgery training, he pursued a fellowship at Johns Hopkins, launching his plastic surgery career before returning to Walter Reed to handle more trauma cases. His work involved extensive microsurgery, such as reconstructing an entire abdominal wall for a survivor of a suicide bombing and performing numerous extremity-free flaps and breast reconstructions using deep inferior epigastric perforator (DIEP) flaps. Over the first seven to eight years, Dr. Chung climbed the Navy's ranks, taking on leadership roles like Chief of Surgery, Chair of the Medical Executive Committee, and ultimately Chief Medical Officer for the San Diego region. Dr. Chung remains passionate about plastic and aesthetic surgery despite his executive responsibilities. Notably, he performs many explant surgeries for patients experiencing issues after long-term breast implant use. Immunosuppression in organ transplants and chronic inflammation In my previous episodes, I've extensively discussed breast implant illness and Dr. Chung agrees that implants may cause more than just localized pain or discomfort. He believes there's something inherently toxic about implants that science can explain and this understanding aligns with groundbreaking surgical advancements by the Nobel Prize winner, Dr. Joseph Murray. Dr. Murray's work on organ transplants demonstrates the need for immunosuppression to prevent rejection. In transplants, immunosuppression is crucial to avoid rejection, but this concept can also apply to implants. Patients often react negatively to treatments like steroids or methotrexate, fearing the medications rather than understanding their role in managing symptoms. We see chronic inflammation in patients with implants, similar to organ rejection. In both scenarios, if the initial post-surgery period goes well, complications are less likely. However, issues during this time can lead to significant problems. For cancer patients undergoing reconstruction, immunosuppression can exacerbate complications, demonstrating the delicate balance required to manage immune responses. Transplant rejection and the use of splint analogy to explain the concept Using analogies from organ transplants helps patients understand that their bodies might be "rejecting" implants, causing chronic inflammation. This perspective can help them grasp the need for proper management and treatment strategies, even if those include higher doses of immunosuppressants like prednisone to manage their symptoms effectively. When it comes to resolving issues with breast implants, focusing on the concept of explants and the importance of addressing capsules surrounding the implants is vital. We use the splinter analogy to explain the body's reaction to foreign objects. Just as a splinter in your finger causes pain and inflammation until it's removed, so does the body react to implants, leading to discomfort and potential toxicity. Removing the splinter provides immediate relief, compared to the relief patients might experience after explant surgery. Dr. Chung appreciates the simplicity of this analogy, which helps patients understand the body's rejection response. He relates it to his experience on transplant rotations, where managing immune responses to transplanted organs was crucial. He emphasizes the importance of detailed procedures in removing implants, akin to meticulous methods used in cancer surgeries to reduce recurrence risks. Breast implant illness, implant removal, and fat transfers as an alternative Both Dr. Chung and I have extensive experience dealing with complications from implants, whether in cancer patients or veterans needing reconstructive surgery. We emphasize that implants can be a necessary part of treatment but also come with risks that must be clearly communicated to patients. Dr. Chung admitted that he initially didn't know much about implant-related issues despite performing many breast augmentations. He often dealt with patients who had capsular contracture, a condition where the scar tissue around the implant tightens and causes pain or deformity. In these cases, he would remove the implant and the capsule and then insert a new implant, only for the problem to eventually recur. I would like to highlight fat transfers as a viable alternative to implants. Fat transfers can help refine and improve reconstructive results by adding volume, achieving a natural look without the risks associated with implants. Dr. Chung supports this approach, noting that while fat transfers don't create the same pressure as implants, they offer a safe and effective option for many patients. Fat transfer vs implant for breast augmentation, with pros and cons for each method Implants provide more projection and pressure, pushing out the skin envelope, especially beneficial for patients with tighter skin or certain deformities like tuberous breasts. Fat transfers, on the other hand, follow the natural curvature of the breast, adding volume and creating a natural look without the risks associated with implants. Fat transfers are particularly effective for patients who have more lax skin, often due to previous pregnancies, breastfeeding, or prior implants, which act like tissue expanders. While fat transfers don't provide the same upper pole fullness or projection as implants, they can achieve a satisfactory result by filling out the skin and providing a natural appearance. The success rate of fat transfers is generally high, especially in younger patients with adequate fat, countering any misconceptions that they don't work well. This method is also frequently used in oncologic reconstruction to refine and improve outcomes. The success of fat transfers is influenced by various factors, each playing a significant role in determining the outcome of the procedure. One crucial factor is the age of the patient. Younger individuals, typically those in their 20s, often experience better outcomes from fat transfers. This is attributed to their more favorable hormone levels and metabolism, which contribute to enhanced tissue regeneration and integration of the transferred fat. Additionally, younger patients tend to have healthier skin with better elasticity, allowing for more seamless integration of the injected fat and resulting in a more natural appearance. Conversely, older patients, particularly those over the age of 35, may encounter challenges that can affect the success of fat transfers. Hormonal imbalances, a common occurrence with age, can impact the body's ability to heal and regenerate tissue effectively. Metabolic issues, such as slower metabolism or insulin resistance, can also hinder the body's ability to process and integrate the transferred fat. Furthermore, poor diet and nutritional deficiencies prevalent in some older individuals can compromise tissue health and overall healing capacity, leading to suboptimal outcomes from fat transfer procedures. On the technical aspects of fat transfer, there is about 20-30% of the injected fat that typically gets absorbed by the body. This process is influenced by the patient's skin condition, with factors like previous pregnancies, weight changes, and age affecting skin expansion and the overall success of the procedure. It's essential for patients and surgeons to recognize these factors and consider them when planning and performing fat transfer procedures. Tailoring the approach to address specific challenges associated with age can help optimize outcomes and ensure patient satisfaction. Moreover, implementing comprehensive preoperative assessments and postoperative care regimens that address hormonal balance, metabolic health, and nutritional status can further enhance the success of fat transfer procedures in older patients. We want to emphasize that the technical process of fat transfer—harvesting, processing, and reinjecting fat—is not the issue. Instead, the patient's overall health and wellness play a critical role in the success and maintenance of the results. That's why I developed a comprehensive program that addresses genetics, detoxification, toxicity issues, gut health, food sensitivities, and hormone balance to optimize recovery and maintain results. Visit our website at https://drrobssolutions.com/ to explore our range of solutions, including high-grade supplements, medical-grade skincare, lab testing, and expert advice. Whether you're recovering from surgery or seeking to enhance your overall wellness, Dr. Rob's Solutions provides the resources and support you need to achieve your goals. Don't let uncertainty hold you back. Trust the experts at Dr. Rob's Solutions to guide you on your journey to healing and wellness. Links and Resurces Dr. Robert Whitfield's Website (https://drrobssolutions.com/) Follow Dr. Rob on Instagram https://www.instagram.com/drrobertwhitfield/ For more information on Virtual and In Person Consultations, we always answer our messenger personally: https://www.drrobertwhitfield.com/contact/ Try the Echo Hydrogen Water Bottle (https://echowater.com/?oid=21&affid=720) Code is DRROB10. About Dr. Rob Dr. Robert Whitfield (https://www.drrobertwhitfield.com/dr-whitfield-2/) In 2012, Dr. Whitfield came to Austin and became renowned for his breast surgery expertise. He set up his own practice in 2017. Here, he offers the men and women of Austin a full range of cosmetic procedures, both surgical and non-surgical, addressing the full array of breast, body and face. Born and bred in Las Vegas, Austin plastic surgeon Dr. Whitfield received his medical degree from the University of Las Vegas School of Medicine. This was followed by six years of surgical training, as well as his plastic surgery residency at Indiana University Medical Center. He returned to Nevada for a one year microsurgery fellowship before settling down to practice and teach at the Medical College of Wisconsin for seven years. Board-certified by the American Board of Plastic Surgery, Dr. Whitfield's approach to medicine has really been shaped by both his upbringing and his education. As a child of the “wild west,” he was born with an adventurous spirit. One of the reasons that he was drawn to plastic surgery is the constant innovation. In the field of plastic surgery, with innovative techniques and technologies developed each year, there are simply issues for which a solution has yet to be invented. Dr. Whitfield tempers his intrepid attitude with Midwestern pragmatism. It makes for a pretty winning combination.
Dr. Jack Cush reviews the news and journal reports from the past 2 weeks on RheumNow.com; but begins with a discussion of what constitutes "immunosuppression" and how it applies to our patients.
During pharmacy school, we had one lecture on solid organ transplantation. With this podcast, we hope to provide tips and tricks to help non-transplant pharmacists decide the best course of action when they come across a solid organ transplant recipient. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
Join us on this episode of the Flex Diet Podcast for a riveting conversation with Dr. Dwayne Jackson as we explore the world of neuro-protection and the critical role nutrition plays in it. We dig into the potentially harmful effects of inflammation and how it can lead to chronic traumatic encephalopathy (CTE). We also highlight the importance of entering sports activities in the least inflammatory state possible and how a balanced diet and supplements can assist.If you enjoyed this podcast, you can get more from me at MikeTNelson.com/podcast. You can see all the other podcasts and guest episodes I've done. Then if you scroll down, you can subscribe to my Fitness Insider Newsletter.Episode Chapters:(0:00:01) - Neuro-Protection and Nutrition(0:07:57) - Colorful Diet(0:13:01) - Exploring Variety in Food and Supplements(0:24:38) - CBD's Impact on Immunosuppression and Neurology(0:29:43) - Microdosing Mushrooms and Lyon's Main(0:39:13) - BHB, Ketone Supplements for Concussions(0:51:40) - Podcast Disclaimer for Health AdviceConnect with Dr. Dwayne Jackson:InstagramWebsitePrevious Podcast:Flex Diet Podcast Episode 202: Cold water immersion and the body's regulation systems: An interview with Dr. Dwayne Jackson
Clinical Journal of the American Society of Nephrology (CJASN)
Drs. Daniel Cattran and Sean Barbour summarize the main results of their study, "Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy," on behalf of their colleagues.
References Luigi Boccherini: Symphony Op. 12 No. 4 in D Minor JCI Insight. 2016 Nov 17; 1(19): e87748 Front Immunol. 2023; 14: 1149366 Adv Biol Regul.2019 Jan;71:41-54. Int. J. Mol. Sci. 2019, 20(6), 1505 --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
On this podcast episode, I cover etanercept pharmacology, adverse effects, drug interactions and much more. Etanercept is classified as a DMARD but is different from older DMARDs in that it is a biologic agent and needs to be injected. Vaccination assessment in patients is important prior to initiating etanercept due to the fact that the medication may blunt the effectiveness of the vaccines. Immunosuppression from etanercept can lead to an increased risk for infection and malignancy.
Guests: Omid McDonald, Vodkow; Andres Ortega & Dr. Mike Van Amburgh, Cornell University; Matheus Santos & Dr. Eduardo Ribeiro, University of Guelph; Dr. Faith Reyes, University of Wisconsin-Madison; Mariana Marinho and Dr. José Santos, University of Florida; and Dr. Alex Tebbe, Purina MillsToday's episode was filmed at the American Dairy Science Association Annual Meeting in Ottawa, Ontario, Canada. Joining us are researchers with abstracts of interest chosen by the Balchem technical team.The first guest is Omid McDonald, founder of Vodcow, the chosen drink at tonight's pubcast. Vodcow is made with a dairy byproduct called milk permeate. The sugar is fermented and turned into alcohol, with which they make vodka and blend it with Canadian Cream. (4:11) Our second guest is Andres Ortega and Dr. Mike Van Amburgh from Cornell University. In Andres's research, to represent mp, they tried to show metabolizing all proteins and break that down into the individual essential and nonessential amino acids. They created two diets; one that met all of the MP requirements and one that didn't. Based on the difference of MP there, they knew how much they would infuse. (12:07) Andre's presentation is titled: Abomasal infusion of essential and non-essential amino acids to evaluate energy and amino acid utilization, productive efficiencies, and metabolism in lactating dairy cattle. Next in our lineup are Matheus Santos and Dr. Eduardo Ribeiro from the University of Guelph. Matheus' research found that lower feed intake and greater body weight had a less positive energy balance. A negative energy balance can lead to high immunosuppression and development of clinical disease. (24:14) Matheus' poster is titled: Prepartum feed intake level is associated with transition metabolism and subsequent milk production in dairy cows. Our third guest is Dr. Faith Reyes from the University of Wisconsin. Dr. Faith said that in dairies, we would like to see decreased competition. Previous literature has shown a linear relationship when you increase the stocking density leads to increased competition. In her research, Dr. Faith found that there was the most competition at a two-to-one stocking density. (35:02) Faith's research is titled: Individual feeding consistency across stocking densities and feed efficiency in lactating cows. Joining us now is Mariana Marinho and Dr. Jose Santos from the University of Florida. Mariana mentioned that more efficient cows have improved rumination per kilogram of intake. More efficient cows also have lower pH and more concentration of ammonia nitrogen. With the findings from her research, Mariana suggests that the site of digestion plays a more important role in differentiating more efficient versus less efficient cows. (52:45) Mariana's presentation is titled: Associations between residual feed intake(RFI) and digestibility or hepatic mitochondrial respiration in Holstein cows. Be sure to subscribe so you don't miss the additional highlights from the 2023 ADSA Annual Meeting in future podcast episodes. Lastly, we are joined by Alex Tebbe from Purina Mills. Alex is focused on transition cows, both the dry period and fresh period and how they are so influential to the cow's long-term performance. Alex said that we could hone in on the nutrition of dry cows and fresh cows to produce a lot of milk in the future. (59:52)Alex's presentation is titled: Dairy nutrition to improve feed utilization - Recognizing the contributions of ADSA Fellow Dr. Bill Weiss beyond prevention of metabolic diseases: Feeding transition dairy cows for optimal performance. If you want one of our new Real Science Exchange t-shirts, screenshot your rating, review, or subscription, and email a picture to anh.marketing@balchem.com. Include your size and mailing address, and we'll get a shirt in the mail to you.
It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: FDA approval for a pancreatic islet cell therapy to treat type 1, stem cell research moves ahead, big news from the ADA Scientific Sessions about what's next for medications like Mounjaro and a pill form of semaglutide. Dexcom announces a sensor for people with type 2 who don't use insulin, Libre moves ahead with Ketone monitoring and more. Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by the T1D Exchange a nonprofit organization dedicated to improving outcomes for the entire T1D population. XX Big week of news following the 2023 ADA Scientific Sessions conference. What follows is just the tip of the information iceberg, so please follow the links in the show notes to much more. -- XX Top story though isn't from ADA – but a new FDA approval.. for a pancreatic islet cell therapy to treat type 1. It's called donislecel, developed from cadaver donors and giving as a single infusion straight into the liver. Immunosuppression is required to maintain cell viability, just as it is required to support a transplanted kidney or other organ. Approval was based on what seems to be a very small study – 30 people with type 1 who had hypoglycemic unawareness and who received between one and three infusions of donislecel. After one year, 11 people did not need to dose insulin.. 10 stayed that way for more than five years. But five people in the study were not able to stop dosing insulin at all. This method is different from what Vertex and Sernova are trying to do with stem cell therapy. https://www.medscape.com/viewarticle/993854 XX Vertex moves forward on their clinical trial of islet stem cell therapy. All six patients treated with VX-880 had undetectable fasting C-peptide (endogenous insulin secretion) at baseline, a history of recurrent SHEs in the year prior to treatment and required an average of 34.0 units of insulin per day. Following treatment, all six patients demonstrated endogenous insulin secretion, improved glycemic control as measured by HbA1c, improved time-in-range on continuous glucose monitoring, and reduction or elimination of exogenous insulin use. Two patient are completely insulin independent after one year – with an A1C of 5.3 compard to 8.6 at baseline.. the other 6.0 with a 7.6 at baseline – again the ”after” number is without taking insulin. As a result of these safety and efficacy data in Parts A and B, the independent data review committee has recommended moving to Part C of the trial, which allows for concurrent dosing of patients at the full target dose of VX-880. https://www.businesswire.com/news/home/20230623446641/en/Vertex-Presents-Positive-VX-880-Results-From-Ongoing-Phase-12-Study-in-Type-1-Diabetes-at-the-American-Diabetes-Association-83rd-Scientific-Sessions XX Sernova also reports good results with their cell pouch system. Five of the six patients who have completed implantation continue to experience insulin independence for periods ranging from six months to more than three years. The sixth patient only recently completed the protocol-defined islet transplants.. so no results yet. There is a second group testing a larger cell pouch. https://www.drugdeliverybusiness.com/sernova-interim-data-cell-pouch-system/ XX Big news from ADA about all of the type 2 and obesity drugs you've likely heard about.. here are some headlines: SURMOUNT-2 clinical trial evaluating tirzepatide – brand name Mounjaro - for weight loss in adults with obesity or overweight and type 2 diabetes. Average weight loss was 15.7% at the highest dose, with many other health benefits such as lower A1C levels; reduction in waist circumference, and body mass index; and improvements in cardiometabolic disease risk factors such as lipid levels, cholesterol, and blood pressure. That 15 percent weight loss was about 34 pounds and the a1c reduction for half of those in the study went down to 5.7 which is considered nondiabetic. Mounjaro is currently approved for type 2 and the FDA could approve Mounjaro regardless of diabetes status later this year. https://diatribe.org/new-lilly-trial-results-show-big-weight-loss-results-positioning-mounjaro-obesity-drug-approval XX A study called PIONEER looks at oral semaglutides – some calling it the Ozempic pill. When compared to other anti-diabetic medications such as Jardiance, Januvia and Victoza, people taking the oral semaglutide say 1% or or more reduction of HbA1c compared to those treated with other anti-diabetic medicines. They also were more like to achieve a 5% or more reduction of body weight. Note: this was not a study comparing a semaglutide pill with the same type of injection. https://www.news-medical.net/news/20230607/Oral-semaglutide-outperforms-other-medications-in-type-2-diabetes-treatment-significantly-reducing-HbA1c-and-body-weight.aspx XX And look for two additional new drugs to treat obesity in the next few years.. orforglipron, is easier to use and to produce, and it will probably be cheaper than existing treatments. The second, retatrutide, has an unprecedented level of efficacy, and could raise the bar for pharmacological obesity treatment. Orforglipron and retatrutide both mimic hormones produced by the lining of the gut in response to certain nutrients. These hormones help to slow the passage of food through the digestive tract and lower appetite by acting on receptors in the brain — both effects that reduce people's desire to eat and help them to lose weight. Orfoglipron is a non-peptide molecule that researchers say is easy to produce and is a pill.. a lower price is anticipated for this one. Retratritude looks like it could help people lose even more weight than Mounjaro. https://www.nature.com/articles/d41586-023-02092-9 XX Dexcom announces a new product in the US – coming in 2024 – designed for people with type 2 who don't use insulin. This will be built on the G7 hardware, but with different software and a 15 day sensor. CEO Kevin Sayer also announced that the G7 will be able to share data direct to the apple watch https://www.businesswire.com/news/home/20230623025076/en/Global-Continuous-Glucose-Monitoring-Pioneer-Dexcom-Reveals-New-Plans-to-Bring-Sensing-Technology-to-Millions-More XX Abbott will partner with Weight Watchers - people who have been prescribed one of Abbott's FreeStyle Libre 14-Day or FreeStyle Libre 2 sensors and who are using the WeightWatchers diet plan to see their CGM data directly in the WeightWatchers app. This is also a study where Abbott will launch two pilot programs directed at using CGM data to help people with Type 2 diabetes adjust and manage their dietary habits, regardless of whether they're on insulin therapy. XX A little bit more news about Abbott's dual glucose and ketone sensor under development. Announced a last year's ADA, the company says it's moving forward through R&D Separately from the Type 2 CGM push, Taub also offered an update on the dual glucose ketone sensor that's currently under development at Abbott and that the company first announced at last year's ADA conference. The sensor will be aimed at catching rising ketone levels as early as possible to help avoid cases of diabetic ketoacidosis. An Abbot executive says – quote - “There's so much that we stand to learn about ketones because there hasn't been a continuous sensor for them before, so there's really very little we know about the evolution of ketones “ https://www.fiercebiotech.com/medtech/ada-abbott-pushes-widespread-cgm-use-type-2-diabetes-weightwatchers-ada-collabs XX Commercial XX Beta Bionics has received FDA 510(k) clearance for the compatibility of the Fiasp Pumpcart prefilled insulin cartridge with the iLet automated insulin-delivery system. The iLet is a bionic pancreas that fully automates 100% of all user insulin doses, providing users with the choice of three insulins, Novolog; Humalog; and Fiasp Pumpcart. The device eases diabetes management in everyday life and almost eliminates the expertise that has been required in the past to set up and manage a traditional insulin pump. In May 2023, Beta Bionics was awarded FDA approval for the iLet device. The iLet manages glucose levels with just a meal announcement and is paired with a Dexcom G6 Continuous Glucose Monitoring System for glucose readings. All that is required for set-up is the user's weight. While there is a need for carbohydrate awareness, no carb counting is necessary. Bolusing, correction factors, insulin-to-carb ratios, and pre-set basal rates are also unnecessary. Beta Bionics president and CEO Sean Saint said: “Beta Bionics has been working tirelessly to create an insulin delivery system that offers less burden and more convenience for the type 1 community. Since launching last month, the iLet bionic pancreas is now available and clinics and users are being trained on its simple design and easy management features. “When Fiasp Pumpcart prefilled cartridges are available, users will save time not having to manually fill cartridges and will have more choice for their diabetes management.” https://www.medicaldevice-network.com/news/beta-bionics-gains-fda-clearance-for-prefilled-insulin-cartridge/ XX Oura – the ring that tracks your sleep – will start sending info to three CGM info companies.. January, Supersapiens and Veri. All three of these companies provide software based off of the Libre CGM. These companies will now be receiving sleep scores and other biometric data from Oura so they can see how these measurements affect users' glucose levels and overall health. https://www.forbes.com/sites/andrewwilliams/2023/06/27/oura-smart-ring-can-be-used-to-help-monitor-blood-sugar/?sh=2520116c2b10 XX Just a fun fact here – there is a Facebook group called type 1 diabetics for 50 plus years. And it looks like this week they passed over 1500 members. XX On the podcast next week.. I sat down with Dexcom's new Chief Commercial officer to talk about their announcements from this week about the type 2 market and other features important to people with type 1. Our last epoisde is all about Kickass Healthy LADA That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.
© 2020-2026 Ivy Podcast Discovery LLC
